Cancer Detection and Experimental Therapeutics (PF-CDET)
Areas Reviewed
- Biomarker identification and pre-clinical development, including liquid biopsy and molecular imaging
- Pre-clinical modeling to identify factors (such as microbiota, pathogens, nutrition, metabolism, oxygen levels, oncogenes, and tumor suppressor genes) and their mechanisms of action contributing to cancer progression
- Mechanisms of therapeutic response, including tumor evolution and treatment resistance
- Mechanisms of treatment-associated morbidities
- Active and passive immune therapies for cancer, adoptive transfer of autologous or allogeneic hematopoietic cells, and targeted delivery of toxic payloads
- Isolation, testing, and synthesis of natural products
- Modification and development of drugs
- Toxicity and effectiveness of therapeutic agents and drug delivery systems (including nanotechnology and microbial strategies)
- Molecular imaging for pre-clinical therapeutic development
- Pharmacology/pharmacogenetics/pharmacogenomics
- Gene therapies and gene target validation
